Results from the research indicate use of ACE in inhibitors and ARBs could prove useful in treating COVID-19 patients of African-American descent. Click here to view the full article at Outsourcing-Pharma.com.

In a Cheddar exclusive, a new partnership between the department of energy and a biotech company that uses artificial intelligence is intended to help researchers more quickly tackle COVID-19. Niven Narain, President, CEO and Co-founder of BERG and Jeremy Smith, Governor’s Chair at the University of Tennessee and the Director of the Oak Ridge National…

Endpoint News May 6, 2020 09:00 AM EDT; Updated 09:34 AM Three weeks after signing a deal with one AI-focused biotech, Boehringer Ingelheim is adding another. The German pharma has announced a partnership with BERG, the data analysis and Bayesian AI company founded over a decade ago by real estate billionaire Carl Berg. Berg will…

BERG’s CEO, Niven R. Narain, recently spoke toRobert Reiss, Founder and CEO, The CEO Forum Group where he discussed BERG’s initiatives with AI, Biology and our approach to efficiently advancing therapeutics into human trials. The summary of Dr. Narain’s discussion with Mr. Reiss is featured on Forbes.com titled “Transforming Drug Discovery Through Artificial Intelligence”. The article highlights…

Hunting for New Drugs with AI The pharmaceutical industry is in a drug-discovery slump. How much can AI help? By David H. Freedman THERE ARE MANY REASONS that promising drugs wash out during pharmaceutical development, and one of them is cytochrome P450. A set of enzymes mostly produced in the liver, CYP450, as it is…

Niven Narain, CEO, President & Co-Founder of BERG, was a guest of the Pod of Asclepius podcast this week. Niven shares insights on how BERG creates value through data platforms and AI in the pharma industry. Find Niven’s episode on iTunes or Google Play or on the podcast website – https://www.podofasclepius.com/season-1